IDEC PHARMACEUTICALS CORP / DE - 10-Q Quarterly Report

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

ý		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2003

OR

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from to

Commission file number: 0-19311

IDEC PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)

Delaware		33-0112644
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

3030 Callan Road, San Diego, CA 92121
(Address of principal executive offices) (Zip code)

(858) 431-8500
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ý No o

Indicate by check mark whether the registrant is an accelerated filer (as defined by Rule 12b-2 of the Exchange Act).

Yes ý No o

As of July 31, 2003, the Registrant had 155,449,170 shares of its common stock, $0.0005 par value, issued and outstanding.

IDEC PHARMACEUTICALS CORPORATION

FORM 10-Q — QUARTERLY REPORT

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2003

TABLE OF CONTENTS

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited)
	Condensed Consolidated Statements of Income — Three and six months ended June 30, 2003 and 2002
	Condensed Consolidated Balance Sheets — June 30, 2003 and December 31, 2002
	Condensed Consolidated Statements of Cash Flows — Six months ended June 30, 2003 and 2002
	Notes to Condensed Consolidated Financial Statements

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

Item 3.	Quantitative and Qualitative Disclosures About Market Risk

Item 4.	Controls and Procedures

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings

Item 4.	Submission of Matters to a Vote of Security Holders

Item 6.	Exhibits and Reports on Form 8-K

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements.

idec pharmaceuticals corporation and subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

	Three months ended June 30,				Six months ended June 30,
	2003		2002		2003		2002
Revenues:
Product sales, net	$	4,980	$	3,300	$	10,642	$	3,300
Revenues from unconsolidated joint business	118,365		92,455		229,276		170,637
Corporate partner revenues	217		1,376		890		2,935
Total revenues	123,562		97,131		240,808		176,872
Operating costs and expenses:
Cost of sales	3,791		889		4,643		889
Research and development	47,440		22,980		76,827		42,229
Selling, general and administrative	29,187		23,224		53,052		42,067
Total operating costs and expenses	80,418		47,093		134,522		85,185
Income from operations	43,144		50,038		106,286		91,687
Interest income, net	3,253		4,397		6,563		8,399
Income before income taxes	46,397		54,435		112,849		100,086
Income taxes	17,631		19,052		42,883		35,030
Net income	$	28,766	$	35,383	$	69,966	$	65,056

Earnings per share:
Basic	$	0.19	$	0.23	$	0.45	$	0.42
Diluted	$	0.17	$	0.20	$	0.41	$	0.37

Shares used in calculation of earnings per share:
Basic	155,171		152,827		154,924		153,128
Diluted	178,308		179,515		178,066		180,965

See accompanying notes to the condensed consolidated financial statements.

idec pharmaceuticals corporation and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value data)

(Unaudited)

	June 30, 2003		December 31, 2002
assets
Current assets:
Cash and cash equivalents	$	292,538	$	350,129
Securities available-for-sale	445,096		437,645
Accounts receivable, net	1,991		4,920
Due from related parties	103,729		100,288
Inventories	38,419		33,665
Deferred tax assets	25,909		27,675
Prepaid expenses and other current assets	20,359		23,288
Total current assets	928,041		977,610

Securities available-for-sale	713,059		660,091
Property and equipment, net	368,503		264,537
Deferred tax assets	73,374		85,197
Restricted cash	25,000		22,500
Investments and other assets	50,600		49,754
Total assets	$	2,158,577	$	2,059,689

liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued costs and expenses	$	51,440	$	55,493
Other current liabilities	806		732
Total current liabilities	52,246		56,225

Notes payable	876,641		866,205
Other liabilities	29,559		27,569

Commitments and contingencies

Stockholders’ equity:
Convertible preferred stock, $0.001 par value	—		—
Common stock, $0.0005 par value	79		78
Additional paid-in capital	998,886		977,672
Accumulated other comprehensive income	3,024		3,764
Retained earnings	333,142		263,176
	1,335,131		1,244,690
Less treasury stock, at cost	135,000		135,000
Total stockholders’ equity	1,200,131		1,109,690
Total liabilities and stockholders’ equity	$	2,158,577	$	2,059,689

See accompanying notes to the condensed consolidated financial statements.

idec pharmaceuticals corporation and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Six months ended June 30,
	2003			2002
Cash flows from operating activities:
Net income	$	69,966		$	65,056
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	6,103			4,540
Non-cash interest expense	18,964			6,808
Deferred income taxes and tax impact from stock options	26,136			33,517
Gain on sales of securities available-for-sale	(1,652		)	(830		)
Other	(96		)	1,721
Change in assets and liabilities:
Accounts receivable, net	2,929			(2,561		)
Due from related parties	(3,441		)	(10,601		)
Inventories	(4,754		)	(13,284		)
Prepaid expenses and other assets	1,035			(21,265		)
Restricted cash	(2,500		)	(9,498		)
Accounts payable and accrued costs and expenses	(4,053		)	5,441
Other liabilities	2,160			(571		)
Net cash provided by operating activities	110,797			58,473

Cash flows from investing activities:
Purchases of securities available-for-sale	(589,698		)	(650,532		)
Sales and maturities of securities available-for-sale	521,551			219,523
Purchases of property and equipment	(109,425		)	(50,846		)
Net cash used in investing activities	(177,572		)	(481,855		)

Cash flows from financing activities:
Proceeds from issuance of notes payable, net	—			696,004
Proceeds from issuance of common stock, net	9,184			12,975
Purchase of common stock for treasury	—			(135,000		)
Net cash provided by financing activities	9,184			573,979

Net increase in cash and cash equivalents	(57,591		)	150,597
Cash and cash equivalents, beginning of period	350,129			425,999
Cash and cash equivalents, end of period	$	292,538		$	576,596

See accompanying notes to the condensed consolidated financial statements.

IDEC PHARMACEUTICALS CORPORATION AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except per share data and unless as otherwise noted)

(Unaudited)

Note 1. Summary of Significant Accounting Policies

The condensed consolidated financial statements as of June 30, 2003, and for the three and six months ended June 30, 2003 and 2002 are unaudited. We have condensed or omitted certain information and footnote disclosures normally included in financial statements presented in accordance with accounting principles generally accepted in the United States of America. We believe the disclosures made are adequate to make the information presented not misleading. However, you should read these condensed consolidated financial statements in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2002.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions relating to the reported amounts of assets, liabilities, revenues and expenses and the related disclosure of contingent assets and liabilities in conformity with accounting principles generally accepted in the United States of America. We regularly evaluate our estimates, including those related to revenue recognition and related allowances, inventory allowances, income taxes including the valuation allowance for deferred tax assets, valuation of long-lived assets and investments, and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from those estimates. Interim results are not necessarily indicative of results for a full year or for any subsequent interim period.

In the opinion of management, these condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of results for the interim periods presented.

Note 2. Significant Events

Upon completion of the merger, our stockholders are expected to own approximately 50.5% of the combined company and Biogen stockholders are expected to own approximately 49.5% of the combined company, on a fully diluted basis. As used in the calculation of the respective ownership interest of each company’s stockholders upon completion of the merger, fully diluted means that the numbers of shares issuable upon conversion or exercise, as applicable, of outstanding convertible preferred stock and promissory notes and stock options with conversion prices or exercise prices, as applicable, that are less than the market price of the applicable company’s common stock minus the number of shares of stock that could be purchased with the proceeds that would be received by the companies from the exercise of such options (assuming such options actually were exercised), are deemed to be outstanding. The merger has been unanimously approved by the board of directors of both us and Biogen. Completion of the merger is subject to the satisfaction of certain conditions, including approval of the merger by the stockholders of both parties, regulatory approvals and other customary closing conditions. We expect the merger to be completed in the fourth quarter of 2003. Either party may be obligated to pay a termination fee of $230 million if the merger agreement is terminated under certain circumstances. We filed a registration statement on Form S-4 with the U.S.

Securities and Exchange Commission on July 16, 2003 that includes a preliminary joint proxy statement/prospectus and other relevant documents in connection with the proposed merger.

On June 19, 2003, we entered into an amended and restated collaboration agreement with Genentech, Inc., or Genentech, for the development of one or more new anti-CD20 antibodies targeting B-cell disorders for a broad range of indications. In connection with the signing of the agreement, we made a $20 million payment to Genentech in June, which has been recorded to research and development expense. We are responsible for a portion of the development costs under the anti-CD20 development program. Until such time as a new product developed under the amended and restated collaboration agreement is approved, the existing RituxanÒ copromotion profit sharing arrangement between us and Genentech, as discussed in Note 3, will remain unchanged. Upon approval of a new anti-CD20 product, the pretax copromotion profit sharing formula for the combination of Rituxan and the new product will change over a period of time to a lower fixed annual profit sharing percentage.

Note 3. Revenues from Unconsolidated Joint Business

Revenues from unconsolidated joint business consist of our share of the pretax copromotion profits generated from our Rituxan copromotion arrangement with Genentech, a related party, reimbursement from Genentech of our Rituxan-related sales force and development expenses and royalty revenue on sales of Rituximab outside the United States by F. Hoffman-La Roche Ltd., or Roche, and Zenyaku Kogyo Co., Ltd., or Zenyaku, both related parties. Rituxan is the trade name in the United Sates, Canada and Japan for the compound Rituximab. Outside the United States, Canada and Japan, Rituximab is marketed as MabThera. In this Form 10-Q, we refer to Rituximab, Rituxan and MabThera collectively as Rituxan, except where we have otherwise indicated. We are copromoting Rituxan in the United States with Genentech under a copromotion arrangement whereby we receive a share of the pretax copromotion profits. The pretax copromotion profit-sharing formula under our Rituxan copromotion arrangement has two tiers. We earn a higher percentage of the pretax copromotion profits at the upper tier once a fixed pretax copromotion profit level is achieved. The profit-sharing formula resets annually at the beginning of each year to the lower tier. We began recording our profit share at the higher percentage during the first quarter of 2003 and 2002.

Under the terms of separate agreements with Genentech, commercialization of Rituxan outside the United States is the responsibility of Roche, except in Japan where Roche markets Rituxan in collaboration with Zenyaku. We receive royalties from Genentech on sales of Rituxan outside the United States, except Canada, by Roche and Zenyaku. Royalties on sales of Rituxan in Canada are received directly from Roche and are included in revenues from unconsolidated joint business in the accompanying condensed consolidated statements of income.

Revenues from unconsolidated joint business for the three and six months ended June 30, 2003 and 2002 consist of the following:

	Three months ended June 30,				Six months ended June 30.
	2003		2002		2003		2002
Copromotion profits	$	99,901	$	77,624	$	192,425	$	143,136
Reimbursement of selling and development expenses	4,537		3,752		8,236		7,384
Royalty revenue on sales of Rituxan outside the U.S., including royalties received directly from Roche	13,927		11,079		28,615		20,117
Total revenues from unconsolidated joint business	$	118,365	$	92,455	$	229,276	$	170,637

Note 4. Inventories

Inventories are stated at the lower of cost, determined by the first-in, first-out method, or market. Included in inventory are raw materials used in the production of clinical products which are recorded to research and development expense when consumed. Inventories consist of the following:

	June 30, 2003		December 31, 2002
Raw materials	$	3,162	$	2,911
Work in process	35,257		30,582
Finished goods	—		172
	$	38,419	$	33,665

ZevalinÒ manufactured prior to approval by the U.S. Food and Drug Administration, or FDA, in February 2002 was recorded as research and development expense.

Note 5. Earnings Per Share

The calculation of basic earnings per share utilizes net income and the weighted-average number of common shares outstanding during the period. The calculation of diluted earnings per share utilizes net income, adjusted for the after-tax amount of interest associated with our convertible promissory notes due 2019, and the weighted-average number of common shares outstanding during the period increased to include the potential dilutive effects of our stock options, convertible preferred stock and convertible promissory notes due 2019. Earnings per share for the three and six months ended June 30, 2003 and 2002 was calculated as follows:

	Three months ended June 30,				Six months ended June 30,
	2003		2002		2003		2002
Numerator:
Net income	$	28,766	$	35,383	$	69,966	$	65,056
Adjustment for interest, net of income tax effect	1,345		1,255		2,616		2,477
Net income, adjusted	$	30,111	$	36,638	$	72,582	$	67,533

Denominator:
Weighted-average common shares outstanding	155,171		152,827		154,924		153,128
Effect of dilutive securities:
Stock options	7,029		9,872		7,034		11,019
Convertible preferred stock	2,173		2,881		2,173		2,881
Convertible promissory notes due 2019	13,935		13,935		13,935		13,937
Dilutive potential common shares	23,137		26,688		23,142		27,837
Weighted-average common shares and dilutive potential common shares	178,308		179,515		178,066		180,965

Basic earnings per share	$	0.19	$	0.23	$	0.45	$	0.42
Diluted earnings per share	$	0.17	$	0.20	$	0.41	$	0.37

Excluded from the calculation of diluted earnings per share for the three and six months ended June 30, 2003 were options to acquire 13.7 million and 18.1 million shares, respectively, of common stock because their effect would be antidilutive. Excluded from the calculation of diluted earnings per share for the three and six months ended June 30, 2002 were options to acquire 5.6 million and 4.6 million shares, respectively, of common stock because their effect would be antidilutive.

Excluded from the calculation of diluted earnings per share for the three and six months ended June 30, 2003 were 8.7 million shares of common stock from the assumed conversion of our 30-year senior convertible promissory notes due 2032 because their effect would be antidilutive. Excluded from the calculation of diluted earnings per share for the three and six months ended June 30, 2002 were 6.3 million and 3.2 million shares, respectively, of common stock from the assumed conversion of our 30-year senior convertible promissory notes due 2032 because their effect would be antidilutive.

Note 6. Stock-Based Compensation

We account for our stock-based employee compensation plans under the recognition and measurement principles of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations. Accordingly, no stock-based employee compensation is reflected in net income as all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net income and earnings per share for the three and six months ended June 30, 2003 and 2002 if we had applied the fair value recognition provisions of Financial Accounting Standards Board, or FASB, Statement No. 123, Accounting for Stock-based Compensation, to stock-

based employee compensation.

	Three months ended June 30,						Six months ended June 30,
	2003			2002			2003			2002
Net income, as reported	$	28,766		$	35,383		$	69,966		$	65,056
Deduct: Total stock-based employee compensation expense determined under the fair value based method for all awards, net of the related income tax effect	(12,752		)	(11,612		)	(23,811		)	(21,939		)
Pro forma net income	$	16,014		$	23,771		$	46,155		$	43,117

Earnings per share:
Basic – as reported	$	0.19		$	0.23		$	0.45		$	0.42
Basic – pro forma	$	0.10		$	0.16		$	0.30		$	0.28

Diluted – as reported	$	0.17		$	0.20		$	0.41		$	0.37
Diluted – pro forma	$	0.09		$	0.14		$	0.27		$	0.25

Note 7. Comprehensive Income

Comprehensive income consists of net income and other comprehensive income. Other comprehensive income includes certain changes in stockholders’ equity that are excluded from net income, specifically unrealized gains and losses on securities available-for-sale, net of the related tax effects. Total comprehensive income for the three months ended June 30, 2003 and 2002 was $28.1 million and $37.3 million, respectively. Total comprehensive income for the six months ended June 30, 2003 and 2002 was $69.2 million and $65.7 million, respectively.

Note 8. Segment Information

We operate in one segment, which is the research, development, manufacture and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. The chief operating decision-makers review our operating results on an aggregate basis and manage our operations as a single operating segment.

Note 9. Guarantees

In November 2002, the FASB issued FASB Interpretation No. 45, Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others, an interpretation of FASB Statements No. 5, 57, and 107 and Rescission of FASB Interpretation No. 34, or FIN No. 45. FIN No. 45 elaborates on the disclosures to be made by a guarantor in its interim and annual financial statements about its obligations under certain guarantees that it has issued. It also requires that a guarantor recognize, at the inception of a guarantee, a liability for the fair value of certain guarantees. The initial recognition and initial measurement provisions of FIN No. 45 are applicable on a prospective basis to guarantees issued or modified after December 31, 2002. Since January 1, 2003, we have not issued or modified any guarantees as defined by FIN No. 45.

Our charter provides for indemnification, to the fullest extent permitted under Delaware law, of any person who is made a party to any action or threatened with any action as a result of such person’s serving or having served as one of our officers or directors or having served, at our request, as an officer or director of another company. We have separate indemnification agreements with certain of our officers and directors. The indemnification does not apply if, among other things, the person’s conduct is finally adjudicated to have been knowingly fraudulent or deliberately dishonest, or to constitute willful misconduct. The indemnification obligation survives termination of the indemnified party’s involvement with us but only as to those claims arising from such person’s role as an officer or director. The maximum potential amount of future payments that we could be required to make under the charter provision and the corresponding indemnification agreements is unlimited; however, we have director and officer insurance policies that, in most cases, would limit our exposure and enable us to recover a portion of any future amounts paid.

We also enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we

generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions.

Note 10. Legal Contingencies

On September 10, 2001, we filed a lawsuit in the federal district court in the Southern District of California against Corixa Corporation, formerly Coulter Pharmaceuticals, Inc., or Corixa, and the University of Michigan seeking declaratory judgment that Zevalin and its use in the treatment of various B-cell non-Hodgkin’s lymphomas, or NHLs, does not infringe certain issued U.S. patents of Corixa regarding products and processes relating to radioimmunotherapy, and a further declaration that Corixa’s patents are invalid. On September 12, 2001, Corixa, GlaxoSmithKline, plc (Corixa’s marketing partner), or Glaxo, and the University of Michigan filed a lawsuit in the federal district court in the District of Delaware against us for patent infringement. The lawsuit claims that we infringe the patents that are the subject of our declaratory judgment action against Corixa. The lawsuit seeks damages and to permanently enjoin us from selling Zevalin. This action has been transferred to the federal district court for the Southern District of California and has been consolidated with our lawsuit. We cannot predict or determine the outcome of this litigation. An unfavorable outcome in this matter could limit our ability to sell Zevalin, could require us to pay damages for past sales of Zevalin and could require that we obtain a license from third parties to sell Zevalin. Any such unfavorable outcome could harm our business and our results of operations.

On February 25, 2003, we filed an additional lawsuit against Corixa and Glaxo in the federal district court in the Southern District of California. The complaint alleges that Corixa’s and Glaxo’s conduct since the recommendation for approval of Bexxar® (tositumomab, iodine I-131 tositumomab) by the FDA’s Oncologic Drugs Advisory Committee, or ODAC, constitutes, or will constitute, infringement of a patent recently issued to us. The complaint seeks available remedies under patent laws, including monetary damages and permanent injunctive relief.

On June 25, 2003, a suit was filed in the Superior Court of California, County of San Diego, on behalf of a purported class of Biogen stockholders against Biogen, us and certain members of Biogen’s board of directors alleging, among other things, that each of Biogen, us and the members of Biogen’s board of directors breached and/or aided in the breach of the other defendants’ breaches of their fiduciary duties of candor, loyalty, due care, independence, good faith and fair dealing by tailoring the structural terms of the merger to meet our specific needs rather than attempting to obtain the highest price reasonably available for Biogen’s stockholders. The complaint seeks, among other things, to enjoin or rescind the merger and to impose constructive trusts in favor of the plaintiff class. We and Biogen intend to defend this action vigorously.

In addition, we are involved in certain other legal proceedings generally incidental to our normal business activities. While the outcome of any such proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any such existing matters would have a material adverse effect on our business or financial condition.

Note 11. New Accounting Pronouncements

In January 2003, the FASB issued FASB Interpretation No. 46, Consolidation of Variable Interest Entities, an interpretation of ARB No. 51, or FIN No. 46. FIN No. 46 requires existing unconsolidated variable interest entities to be consolidated by their primary beneficiaries if the entities do not effectively disperse risks among parties involved. Variable interest entities that effectively disperse risk will not be consolidated unless a single party holds an interest or combination of interests that effectively recombines risks that were previously dispersed. FIN No. 46 also requires enhanced disclosure requirements related to variable interest entities. FIN No. 46 applies immediately to variable interest entities created after January 31, 2003, and to variable interest entities in which an enterprise obtains an interest after that date. It applies in the first fiscal year or interim period beginning after June 15, 2003 to variable interest entities in which an enterprise holds a variable interest that it acquired before February 1, 2003. We do not currently participate in any variable interest entities as defined by FIN No. 46. Therefore, we do not believe that the adoption of this accounting pronouncement will have a material impact on our financial statements.

In May 2003, the FASB issued Statement of Financial Accounting Standards No. 150, Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity, or Statement No. 150. Statement No. 150 establishes standards for how to classify and measure certain financial instruments with characteristics of both

liabilities and equity. Financial instruments that are within the scope of Statement No. 150 are required to be classified as a liability or, in some circumstances, as an asset. Many of these financial instruments were previously classified as equity. Statement No. 150 is immediately effective for financial instruments entered into or modified after May 31, 2003. It is effective in the first fiscal year or interim period beginning after June 15, 2003 for financial instruments existing prior to June 1, 2003. We do not currently hold any financial instruments that are within the scope of Statement No. 150. Therefore, we do not believe that the adoption of this accounting pronouncement will have a material impact on our financial statements.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

OVERVIEW

We are primarily engaged in the research, development, manufacture and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases.

In February 2002, Zevalin became the first radioimmunotherapy approved by the FDA for the treatment of certain B-cell NHLs. We have retained all marketing and distribution rights to Zevalin in the United States and have granted marketing and distribution rights outside the United States to Schering Aktiengesellschaft, or Schering AG. The European Medicines Evaluation Agency has accepted for filing the Zevalin Marketing Approval Authorization, submitted by Schering AG in the European Union. The “Summary of Product Characteristics” was approved by the European Committee for Proprietary Medicinal Products for the treatment of adult patients with Rituximab relapsed or refractory CD20+ follicular B-cell NHL. Final approval is pending.

Our other product, Rituxan, is being copromoted in the United States under a copromotion arrangement with Genentech, where we receive a share of the pretax copromotion profits from the sale of Rituxan. Under the copromotion arrangement, we share responsibility with Genentech for selling and continued development of Rituxan in the United States. Continued development of Rituxan includes conducting supportive research on Rituxan, post-approval clinical studies and obtaining approval of Rituxan for potential additional indications. Genentech provides the support functions for the commercialization of Rituxan in the United States including marketing, customer service, order entry, distribution, shipping, billing and since September 1999, all worldwide bulk manufacturing. Commercialization of Rituxan outside the United States is the responsibility of Roche, except in Japan where Roche markets Rituxan in collaboration with Zenyaku. We receive royalties on Rituxan sales outside the United States. We amended and restated our collaboration agreement with Genentech on June 19, 2003.

Our revenues include revenues from product sales of Zevalin, revenues from unconsolidated joint business and corporate partner revenues. Since the commercialization of Rituxan in November 1997, our revenues have depended primarily upon the sale of Rituxan.

We have incurred increasing annual operating expenses and, with the commercialization of Rituxan and Zevalin, we expect these trends to continue. From our inception in 1985 through 1997, we incurred annual operating losses. Our ongoing profitability will be dependent upon the continued commercial success of Rituxan, the commercial success of Zevalin, product development and revenues from the achievement of product development objectives and licensing transactions. As of June 30, 2003, we had retained earnings of $333.1 million.

On June 20, 2003, we entered into an Agreement and Plan of Merger with Biogen, Inc., or Biogen, under which a newly created IDEC subsidiary will merge with and into Biogen in a transaction to be accounted for as a purchase under accounting principles generally accepted in the United States of America, with us treated as the acquiror. Under the terms of the merger agreement, each share of Biogen common stock outstanding on the closing date of the merger will be exchanged for 1.15 shares of our common stock, plus cash in lieu of fractional shares. In addition, each option to purchase Biogen common stock that is outstanding on the closing date will be assumed by us and will thereafter constitute an option to acquire shares of our common stock determined by multiplying the number of shares of Biogen common stock subject to the option immediately prior to the merger by 1.15, rounded down to the nearest whole share, with an exercise price equal to the exercise price of the assumed Biogen option divided by 1.15, rounded up to the nearest whole cent. Each of these options will be subject to the same terms and conditions that were in effect for the Biogen options being replaced. Upon completion of the merger, our stockholders are expected to own approximately 50.5% of the combined company and Biogen stockholders are expected to own approximately 49.5% of the combined company, on a fully diluted basis. The merger has been unanimously approved by the board of directors of both us and Biogen. Completion of the merger is subject to the satisfaction of certain conditions, including approval of the merger by the stockholders of both parties, regulatory approvals and other customary closing conditions. We expect the merger to be completed in the fourth quarter of 2003. Either party may be obligated to pay a termination fee of $230 million if the merger agreement is terminated under certain circumstances. We filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on July 16, 2003 that includes a preliminary joint proxy statement/prospectus and other relevant documents in connection with the proposed merger.

CRITICAL ACCOUNTING PRINCIPLES AND ESTIMATES

The preparation of our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires our management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. We regularly evaluate our estimates, including those related to revenue recognition and related allowances, inventory allowances, income taxes including the valuation allowance for deferred tax assets, valuation of long-lived assets and investments, and contingencies and litigation. These estimates are based on currently available information and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could vary from these estimates under different assumptions or conditions.

Critical accounting policies and estimates are defined as those that are both most important to the portrayal of our financial condition and results of operations and require management’s most subjective judgments. We have identified the following as the most critical accounting policies and estimates used in the preparation of our condensed consolidated financial statements. See Note 1 to our annual consolidated financial statements included in our 2002 Annual Report on Form 10-K for a description of our accounting policies.

Revenue recognition and related allowances: Revenues from sales of Zevalin are recognized upon shipment and transfer of title and risk of loss to the customer. We record allowances for estimated uncollectible accounts receivable, product returns and Medicaid rebates at the time of sale. Our estimates for uncollectible accounts receivable, product returns and Medicaid rebates are based primarily on our experience with Zevalin to date, historical experience with Rituxan and other factors, updated for changes in facts and circumstances, as appropriate. If actual future results vary, we may need to adjust our estimates, which could have an impact on earnings in the period of adjustment.

Revenues from unconsolidated joint business consist of our share of the pretax copromotion profits generated from our Rituxan copromotion arrangement with Genentech, reimbursement from Genentech of our Rituxan-related sales force and development expenses and royalty revenue from sales of Rituxan outside the United States by Roche and Zenyaku. Under our copromotion arrangement with Genentech, all sales of Rituxan in the United States and the associated costs and expenses are recognized by Genentech and we record our share of the pretax copromotion profits on a quarterly basis. Pretax copromotion profits under the copromotion arrangement are derived by taking net sales of Rituxan to third-party customers in the United States less cost of sales, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech and us. Our profit-sharing formula with Genentech has two tiers; we earn a higher percentage of the pretax copromotion profits at the upper tier once a fixed pretax copromotion profit level is met. The profit-sharing formula resets annually at the beginning of each year to the lower tier. We record our royalty revenue with a one-quarter lag.

Corporate partner revenues, which consist of contract revenues and license fees, are recognized in accordance with the provisions of Securities and Exchange Commission Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements, or SAB No. 101.

Revenue is not recognized unless collectibility is reasonably assured and the earnings process is complete. We believe our revenue recognition policies are in compliance with SAB No. 101.

Income taxes: In preparing our condensed consolidated financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial statement purposes. These differences result in deferred tax assets and liabilities, which are included in our condensed consolidated balance sheet. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Our estimates of future taxable income are derived from, among other items, our estimates of future deductions related to stock options. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance which could materially impact our financial position and results of operations.

Inventories: Inventories are stated at the lower of cost, determined by the first-in, first-out method, or market. If inventory costs were to exceed expected market value due to excess, obsolescence or unmarketability, we would record allowances for the difference between the cost and the market value. Included in inventory are raw materials used in the production of clinical products which are recorded to research and development expense when consumed. Zevalin manufactured prior to FDA approval in February 2002 was recorded as research and development expense.

RESULTS OF OPERATIONS

Product Sales, Net: Net product sales for the three and six months ended June 30, 2003 were $5.0 million and $10.6 million, respectively, compared to $3.3 million for the three and six months ended June 30, 2002, and consisted solely of net sales of Zevalin in the United States. Zevalin was approved by the FDA for the treatment of certain B-cell NHLs in February 2002 and we commenced selling Zevalin in April 2002. Cost of sales as a percentage of product sales was 76% and 44%, respectively, for the three and six months ended June 30, 2003, compared to 27% for the three and six months ended June 30, 2002. Cost of sales for the three and six months ended June 30, 2003 included a $3.1 million write-down of Zevalin commercial inventory that did not meet quality specifications. Cost of sales for the three and six months ended June 30, 2002 included certain manufacturing variances of $0.6 million. Historically, cost of sales has consisted primarily of contractual royalties owed on Zevalin sales. Zevalin manufactured prior to FDA approval in February 2002 was recorded as research and development expense. Zevalin sales to date have solely consisted of Zevalin produced prior to FDA approval in February 2002. Cost of sales as a percentage of product sales for the three and six months ended June 30, 2003 would have been approximately 18% and 19%, respectively, had Zevalin produced prior to FDA approval been capitalized as inventory and excluding the $3.1 million write-down of Zevalin commercial inventory that did not meet quality specifications. Cost of sales as a percentage of product sales for the three and six months ended June 30, 2002 would have been approximately 12% had Zevalin produced prior to FDA approval been capitalized as inventory and after adjusting for the manufacturing variances.

Revenues from Unconsolidated Joint Business: Revenues from unconsolidated joint business for the three and six months ended June 30, 2003 and 2002, consist of the following:

	Three months ended June 30,				Six months ended June 30,
	2003		2002		2003		2002
Copromotion profits	$	99,901	$	77,624	$	192,425	$	143,136
Reimbursement of selling and development expenses	4,537		3,752		8,236		7,384
Royalty revenue on sales of Rituxan outside the U.S., including royalties received directly from Roche	13,927		11,079		28,615		20,117
Total revenues from unconsolidated joint business	$	118,365	$	92,455	$	229,276	$	170,637

Under our copromotion arrangement with Genentech, our pretax copromotion profit-sharing formula has two tiers. We earn a higher percentage of the pretax copromotion profits at the upper tier once a fixed pretax copromotion profit level is met. The profit-sharing formula resets annually at the beginning of each year to the lower tier. We began recording our profit share at the higher percentage during the first quarter of 2003 and 2002.

Rituxan net sales to third-party customers in the United States recorded by Genentech for the three and six months ended June 30, 2003 amounted to $328 million and $638 million, respectively, compared to $257 million and $492 million for the comparable periods in 2002. This increase was primarily due to increased market penetration in treatments of B-cell NHLs and increases in the wholesale price of Rituxan effective on March 1, 2002 and March 1, 2003.

Our royalty revenue on sales of Rituxan outside the United States is based on Roche’s and Zenyaku’s end-user sales and is recorded with a one-quarter lag. The increase in royalty revenue for the three and six months ended June 30, 2003 is primarily due to higher sales of Rituxan outside the United States resulting from increased penetration of certain foreign markets, primarily Western Europe, Australia and Canada.

Corporate Partner Revenues: Corporate partner revenues for the three months ended June 30, 2003 totaled $0.2 million compared to $1.4 million for the comparable period in 2002. The decrease in corporate partner

revenues for the three months ended June 30, 2003 is primarily the result of the recognition of a $1 million milestone payment under our collaborative development agreement with Mitsubishi Pharma Corporation in the comparable period in 2002. Corporate partner revenues for the six months ended June 30, 2003 totaled $0.9 million compared to $2.9 million for the comparable period in 2002. The decrease in corporate partner revenues for the six months ended June 30, 2003 is the result of the recognition of a $1 million milestone payment under our collaborative development agreement with Mitsubishi Pharma Corporation in the comparable period in 2002 and decreased research and development funding under our collaborative agreements.

Corporate partner revenues are, in part, dependent upon achievement of certain research and development and commercialization objectives and, accordingly, may vary from year to year. The magnitude and timing of corporate partner revenues may influence our level of profitability. For example, a further delay in Zevalin approval in Europe will result in a delay in the payment and recognition of a $10 million product approval milestone from Schering AG.

Research and Development Expenses: Research and development expenses totaled $47.4 million and $76.8 million for the three and six months ended June 30, 2003, respectively, compared to $23.0 million and $42.2 million for the comparable periods in 2002. The increase in research and development expenses for the three and six months ended June 30, 2003 is primarily due to a $20 million payment to Genentech in conjunction with signing the amended and restated collaboration agreement in June 2003, which was recorded to research and development expense. Additionally, the increase in research and development expenses is due to increased personnel, facility and contract research and development expenses related to our new oncology collaboration with Biogen entered into in January 2003.

We do not anticipate manufacturing bulk Zevalin inventory during the remainder of 2003. In 2003, our manufacturing facilities will be used primarily to support products in development which will cause the majority of the costs of our manufacturing operations to be recorded as research and development expense. Such costs were capitalized into inventory in 2002 to the extent they related to the manufacture of Zevalin. In the future we expect to continue incurring substantial additional research and development expenses due to:

• preclinical and clinical testing of our various products under development;

• expansion or addition of research and development programs;

• technology in-licensing;

• regulatory-related expenses;

• expansion of clinical manufacturing capabilities; and

• facilities expansion.

Selling, General and Administrative Expenses: Selling, general and administrative expenses totaled $29.2 million and $53.1 million for the three and six months ended June 30, 2003, respectively, compared to $23.2 million and $42.1 million for the comparable periods in 2002. This increase is primarily due to expansion of our sales, marketing and administrative functions to support the commercialization of Zevalin, increased legal fees to protect our intellectual property rights and general increases in general and administrative expenses to support overall organizational growth. Selling, general and administrative expenses are expected to increase in the foreseeable future to support the following:

• marketing and administration related to the commercialization of Zevalin;

• manufacturing capacity expansion;

• clinical trials;

• research and development; and

• protection and enforcement of our intellectual property rights for Zevalin and our product candidates.

Interest Income, Net: Interest income totaled $8.1 million and $16.3 million for the three and six months ended June 30, 2003, respectively, compared to $8.5 million and $14.4 million for the comparable periods in 2002. The decrease in interest income for the three months ended June 30, 2003 is due to lower interest rates realized on our cash, cash equivalents and securities available-for-sale. The increase in interest income for the six months ended June 30, 2003 is due to higher cash balances from the issuance of our 30-year senior convertible promissory notes, or senior notes, in April and May 2002.

Interest expense totaled $4.9 million and $9.8 million for the three and six months ended June 30, 2003, respectively, compared to $4.1 million and $6.0 million for the comparable periods in 2002. This increase is due to noncash interest charges relating to the issuance of our senior notes in April and May 2002.

Income Taxes: Our effective tax rate for the three and six months ended June 30, 2003 was 38% compared to 35% for the comparable periods in 2002. Our effective tax rates in 2003 and 2002 were less than a normal statutory rate due primarily to the generation of tax credits by our research and development activities. We expect that our effective tax rate in the future will continue to be lower than a normal statutory rate as a result of our continued research and development efforts which we expect will generate tax credits.

LIQUIDITY AND CAPITAL RESOURCES

We have financed our operating and capital expenditures since inception principally through sales of equity securities, funds from our unconsolidated joint business arrangement related to the sales of Rituxan, corporate partner revenues, lease financing transactions, debt financing transactions and interest income. We expect to finance our current and planned operating requirements principally through cash on hand, funds from our unconsolidated joint business arrangement related to the sale of Rituxan, funds from commercial sales of Zevalin and funds from existing collaborative agreements and contracts. We believe that these funds will be sufficient to meet our operating requirements for the foreseeable future. Existing collaborative research agreements and contracts, however, could be canceled by the contracting parties. In addition, we may from time to time seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources. Additional funds may not be obtainable through these sources on acceptable terms, if at all. If adequate funds are not obtainable from our unconsolidated joint business arrangement related to the sale of Rituxan, commercial sales of Zevalin, operations or additional sources of financing, our business could be harmed. Our working capital and capital requirements will depend upon numerous factors, including:

• continued commercial success of Rituxan;

• commercial success of Zevalin;

• timing and expense of obtaining regulatory approvals;

• funding and timing of payments related to several material capital projects, including the development of our large-scale manufacturing facility and corporate headquarters and research and development campus;

• progress of our preclinical and clinical testing;

• fluctuating or increasing manufacturing requirements and research and development programs;

• levels of resources that we devote to the development of manufacturing, sales and marketing capabilities, including resources devoted to the marketing of Zevalin;

• technological advances;

• status of competitors;

• our ability to establish collaborative arrangements with other organizations; and

• working capital required to satisfy the put options related to our senior notes.

Until required for operations, we invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, foreign and United States government instruments and other readily marketable debt instruments in accordance with our investment policy.

At June 30, 2003, we had $1.5 billion in cash, cash equivalents and securities available-for-sale compared to $1.4 billion at December 31, 2002. Sources of cash, cash equivalents and securities available-for-sale during the six months ended June 30, 2003, included $110.8 million from operations and $9.2 million from the issuance of common stock under employee stock option and purchase plans. Uses of cash, cash equivalents and securities available-for-sale during the six months ended June 30, 2003 consisted of $109.4 million to fund construction projects and purchase capital equipment.

In April and May 2002, we raised through the issuance of our senior notes due 2032, approximately $696.0 million, net of underwriting commissions and expenses of $18.4 million. Simultaneously with the issuance of the senior notes, we used a portion of the proceeds to fund the repurchase of $135.0 million of our outstanding common stock. The senior notes are zero coupon and were priced with a yield to maturity of 1.75% annually. We will pay contingent cash interest to the holders of these senior notes during any six-month period commencing on or after April 30, 2007 if the average market price of the senior notes for a five-trading-day measurement period preceding

such six-month period equals 120% or more of the sum of the issue price and accrued original issue discount for such senior note. The contingent interest payable per senior note in respect of any quarterly period within such six-month period where contingent interest is determined to be payable will equal the greater of (1) the amount of regular cash dividends paid by us per share on our common stock during that quarterly period multiplied by the then applicable conversion rate or (2) 0.0625% of the average market price of a senior note for the five-trading-day measurement period preceding such six-month period, provided that if we do not pay regular cash dividends during a semiannual period, we will pay contingent interest semiannually at a rate of 0.125% of the average market price of a senior note for the five-trading-day measurement period immediately preceding such six-month period.

Upon maturity, the senior notes will have an aggregate principal face value of $1.2 billion. Each one-thousand dollar aggregate principal face value senior note is convertible at the holder’s option at any time through maturity into 7.1881 shares of our common stock at an initial conversion price of $82.49. In addition, holders of the senior notes may require us to purchase all or a portion of the senior notes on April 29, 2005, 2007, 2012 and 2017 at a price equal to the issue price plus the accrued original issue discount to the date of purchase, payable at our option in cash, our common stock or a combination thereof. In addition, if a change in control in our company occurs on or before April 29, 2007, holders of the senior notes may require us to purchase all or a portion of their senior notes for cash. We have the right to redeem all or a portion of the senior notes for cash at any time on or after April 29, 2007 at set prices.

In February 1999, we raised through the sale of our subordinated convertible promissory notes due 2019, or subordinated notes, approximately $112.7 million, net of underwriting commissions and expenses of $3.9 million. The subordinated notes are zero coupon and were priced with a yield to maturity of 5.5% annually. Upon maturity, the subordinated notes will have an aggregate principal face value of $345.0 million. Each one-thousand dollar aggregate principal face value subordinated note is convertible at the holders’ option at any time through maturity into 40.404 shares of our common stock at an initial conversion price of $8.36. We are required under the terms of the subordinated notes, as of 35 business days after a change in control occurring on or before February 16, 2004, to purchase any subordinated note at the option of its holder at a price equal to the issue price plus accrued original issue discount to the date of purchase. Additionally, the holders of the subordinated notes may require us to purchase the subordinated notes on February 16, 2004, 2009 or 2014 at a price equal to the issue price plus accrued original issue discount to the date of purchase payable at our option in cash, our common stock or a combination thereof. We have the right to redeem the subordinated notes on or after February 16, 2004.

We have an agreement with MDS Canada, Inc., formerly MDS Nordion, Inc., or MDS Canada, for the development and supply of the radioisotope yttrium-90 required for the therapeutic use of Zevalin. Under the terms of our agreement with MDS Canada, we are obligated to make periodic payments into an escrow account. These funds secure certain obligations we have under our agreement regarding MDS Canada’s obligation to establish a new facility to supply us with yttrium-90. As of June 30, 2003, we have paid $25.0 million into this escrow fund.

We own approximately 42.6 acres of land in San Diego, California where we are developing administrative offices and a research and development facility. The first phase of construction is expected to be completed in mid 2004 at an estimated total cost of approximately $178 million to be funded from our working capital. As of June 30, 2003, we have invested approximately $22.1 million in the construction of this campus.

We own approximately 87 acres of land in Oceanside, California where we are developing a large-scale manufacturing facility that we anticipate using to commercialize our products currently in clinical trials if they are approved by the FDA. This facility will allow us to better control the manufacture of our products, reducing our reliance on contract manufacturers, as well as reducing our commercial supply risk. We expect the new facility to be mechanically completed in 2005, followed by commissioning and validation in 2006. Total costs of this facility upon completion are estimated to be approximately $400 million which will be funded from our working capital. As of June 30, 2003, we have invested approximately $180.3 million in the construction of this large-scale manufacturing facility.

In connection with our research and development efforts, we have entered into various collaborative arrangements under which we may be obligated to pay royalties or milestone payments if product development is successful. It is not anticipated that the aggregate of any royalty or milestone obligations under these arrangements will be material to our operations.

In January 2003, we entered into a collaboration agreement with Biogen under which we will collaborate on the development of three oncology therapeutics from Biogen’s pipeline of early-stage product candidates, including IDEC-201. Under the terms of this agreement, we will be responsible for the development costs of the product candidates, until that time, if any, when Biogen exercises opt-in rights with respect to each specific product candidate. If Biogen exercises its opt-in rights for a specific product, we will share equally with Biogen all subsequent costs and economic benefit related to that specific product. If Biogen chooses not to exercise its opt-in rights, we will pay royalties to Biogen for future sales, if any, of the specific products. This agreement will terminate if the merger with Biogen is completed.

FORWARD-LOOKING INFORMATION AND RISK FACTORS

THAT MAY AFFECT FUTURE RESULTS

This Form 10-Q contains forward-looking statements based on our current expectations. These statements include, without limitation, statements about market opportunity, our growth and sale strategies and our expectations, plans and objectives. In some cases, you can identify these statements by terminology such as anticipate, believe, estimate, expect, intend, may, plan, should or will or similar phrases or expressions. You should be aware that these statements are projections or estimates as to future events, and actual results may differ materially.

In addition to the other information contained in this Form 10-Q, you should consider the following risk factors which could affect our actual future results and could harm our business, financial condition and results of operations. The risks and uncertainties described below are not the only risks facing us and additional risks and uncertainties may also harm our business.

Our Revenues Rely Significantly on Rituxan Sales.

Our revenues currently depend substantially upon continued sales of Rituxan. For each of the six months ended June 30, 2003 and the year ended December 31, 2002, approximately 95% of our revenues were derived from our joint business arrangement related to the sale of Rituxan. We cannot assure you that Rituxan will continue to be accepted in the United States or in any foreign markets or that Rituxan sales will continue to increase. A number of factors may affect the rate and level of market acceptance of Rituxan, including:

• the perception by physicians and other members of the healthcare community of its safety and efficacy or that of competing products, if any;

• the effectiveness of our and Genentech’s sales and marketing efforts in the United States, the effectiveness of Roche’s sales and marketing efforts outside the United States, and the effectiveness of the sales and marketing efforts of Zenyaku and Roche in Japan;

• unfavorable publicity concerning Rituxan or similar drugs;

• the price of Rituxan relative to other drugs or competing treatments;

• the availability and level of third-party reimbursement for Rituxan; and

• regulatory developments related to the manufacture or continued use of Rituxan.

Given our current reliance on Rituxan as the principal source of our revenue, any material adverse developments with respect to the commercialization of Rituxan may cause our revenue to decrease and may cause us to incur losses in the future.

If We Fail to Commercialize Zevalin Successfully in the United States, to Obtain Marketing Approval for Zevalin in Europe or to Commercialize Zevalin Successfully in Europe, Our Business Could Be Harmed.

Our radioimmunotherapy product Zevalin was approved by the FDA for marketing and sale in the United States in February 2002 and we began selling the product in April 2002. We cannot assure you that Zevalin will be accepted or widely used by physicians and other members of the healthcare community in the United States. Further, marketing approval for Zevalin in Europe is pending and we cannot be certain that, even if marketing approval is obtained, our exclusive worldwide marketing partner, Schering AG, will be able to successfully commercialize Zevalin in Europe. Factors that might impact the success of Zevalin include:

• the perception by physicians and other members of the healthcare community of its safety and efficacy or that of competing products;

• unfavorable publicity concerning Zevalin or similar drugs;

• its price relative to other drugs or competing treatments;

• the availability and level of third-party reimbursement;

• regulatory developments related to the manufacture or continued use of Zevalin;

• successful commercialization of Bexxarâ (tositumomab, iodine I-131 tositumomab) or other competitive products; and

• an adverse outcome of our patent litigation.

In addition, we have limited marketing support service experience and, therefore, we are dependent upon outside contractors to meet those needs for Zevalin. For example, we rely upon a third-party logistics distributor to provide customer service, order entry, shipping and billing for Zevalin. Customer reimbursement assistance for Zevalin is provided by a separate outside contractor. We cannot assure that the integration of these marketing support services can be coordinated successfully. Further, given our limited marketing and sales experience, we cannot assure you that we will be successful in selling Zevalin in the United States.

We rely on MDS Canada to provide the yttrium-90 radioisotope required for therapeutic use of Zevalin, and we rely on third parties for various manufacturing steps in the production of Zevalin. In addition, there are currently only two sources approved by the FDA to supply the indium-111 isotope required for the imaging use of Zevalin. If we were to lose the services of any of these parties, we would be forced to find other providers, which could delay our ability to sell Zevalin. In addition, each of these third-party providers is subject to continuing inspection by the FDA or comparable agencies in other jurisdictions. A delay or an interruption in the manufacture of Zevalin or the production or availability of the yttrium-90 radioisotope or the indium-111 isotope for any reason, including as a result of a failure to pass any regulatory agency inspection, could significantly impair our ability to sell Zevalin.

We May Be Unable to Develop and Commercialize New Products.

Our future results of operations depend to a large extent upon our ability to successfully develop and commercialize new products in a timely and competitive manner. As a result, we must continue to develop, test and manufacture new products and then must meet regulatory standards and obtain regulatory approvals for any new products. Our products currently in development may not receive the regulatory approvals from the FDA or comparable agencies in other jurisdictions necessary to market these products. Additionally, the development and commercialization process is time-consuming and costly, and we cannot assure you that any of our products, if and when developed and approved, will be successfully commercialized or competitive in the marketplace. Our business could be harmed if we were to experience delays or unanticipated costs in any part of the development process, if we were unable to obtain the regulatory approvals required to market the products we may develop, if we are unable to effectively commercialize products we may develop, or if we cannot secure or maintain manufacturing facilities in compliance with all applicable regulatory requirements.

We Have Limited Manufacturing Experience and Rely Heavily on Contract Manufacturers.

We rely heavily upon third-party manufacturers to manufacture significant portions of Zevalin and our product candidates. Our current manufacturing capacity is limited. Our manufacturing experience to date has been limited to the production of preclinical and clinical quantities of product candidates, approximately three years of commercial production of bulk Rituxan and portions of our commercial requirements of the Zevalin bulk antibody. We have no fill/finish experience or capacity, and we do not have experience manufacturing in the field of chelates or radioisotopes, which are required for our production of Zevalin. Therefore, we rely entirely upon third parties for fill/finish services as well as the manufacture of most of our product components. We cannot assure you that either our manufacturing facilities or our ability to sustain ongoing production of our products will be able to meet our expectations. If our current third-party manufacturers or service providers fail to meet our expectations, we may not be able to enter into satisfactory agreements with other third party manufacturers or service providers.

Zevalin has multiple components that require successful coordination among ourselves and several third-party contract manufacturers and suppliers. We may not be able to integrate and coordinate successfully our contract manufacturers and suppliers. In addition, our contract manufacturers and suppliers are required to maintain

compliance with current Good Manufacturing Practices, or cGMP, and are subject to inspections by the FDA or comparable agencies in other jurisdictions to confirm this compliance. Any changes of suppliers or modifications of methods of manufacturing require amending our application to the FDA and ultimate amendment acceptance by the FDA prior to release of product to the market place. The inability of our contract manufacturers and suppliers to demonstrate ongoing cGMP compliance and produce Zevalin components could interrupt commercial supply of Zevalin. If Zevalin production was interrupted or our third-party manufacturer was unable to manufacture adequate commercial quantities of Zevalin in a timely manner, it could harm our business.

We rely on Genentech for all Rituxan manufacturing to meet worldwide requirements. We cannot ensure that Genentech will manufacture and fill/finish Rituxan in sufficient quantities and on a timely and cost-effective basis or that Genentech will obtain and maintain all required manufacturing approvals. Genentech’s failure to manufacture and fill/finish Rituxan or obtain and maintain required manufacturing approvals could harm our business.

From our manufacturing facilities, we have manufactured and will continue to manufacture our own commercial requirements of the bulk antibody and other kit components for Zevalin. We cannot assure you that our manufacturing performance will meet our expectations. Our inability to maintain regulatory approval of our manufacturing facility for Zevalin would harm our ability to timely produce commercial supplies of the Zevalin antibody. To the extent we cannot produce our own biologics, we will need to rely on third-party manufacturers, of which there are only a limited number capable of manufacturing biologics products as contract suppliers. We cannot be certain that we could reach agreement on reasonable terms, if at all, with those manufacturers.

Poor performance or coordination on our part or that of our third-party manufacturers or service providers could harm our business.

We Rely Heavily on a Limited Number of Suppliers.

Some materials used in Rituxan, Zevalin and our product candidates are currently available only from a single supplier or a limited number of suppliers. Some of these suppliers are subject to ongoing FDA approvals or other governmental regulations. Any interruption or delay in our supply of materials required to sell our products could harm our business if we were unable to obtain an alternative supplier for these materials in a cost-effective and timely manner. Additional factors that could cause interruptions or delays in our source of materials include limitations on the availability of raw materials or manufacturing performance experienced by our suppliers and a breakdown in our commercial relations with one or more suppliers. These factors may be completely out of our control.

For example, we have entered into an agreement with MDS Canada, the commercial supplier of the yttrium-90 radioisotope required for the therapeutic use of Zevalin, and will rely upon MDS Canada to supply our clinical and commercial requirements. If MDS Canada does not maintain FDA approvals or approvals of comparable agencies in other jurisdictions to produce the radioisotope yttrium-90 for Zevalin, or if we are unable to receive an adequate supply of this radioisotope for any other reason, including those described above, we would be unable to sell Zevalin for therapeutic use unless we were to obtain a new supplier. We are aware of other entities that may be able to provide the radioisotope that we need for the therapeutic use of Zevalin but we believe that these suppliers would be required to apply for additional governmental approvals to do so. The process of establishing a relationship with another supplier and the process of obtaining the required governmental approvals would be time-consuming and uncertain. We cannot assure you that we could reach an agreement with another supplier in a timely manner or on commercially reasonable terms, if at all. As a result of these concerns, if we were to lose our supply or were unable to receive sufficient quantities of the radioisotope from our sole supplier, our ability to sell Zevalin could be harmed which, in turn, could harm our business.

We Have Limited Sales and Marketing Experience.

We have limited experience with commercial sales and marketing, based entirely upon our launch and subsequent sales of Rituxan. Zevalin is our first product to be marketed exclusively by us in the United States. Outside the United States, our strategy for future products is to pursue and to rely solely upon collaborations with established pharmaceutical companies for marketing, distribution and sale of our products. We currently have no plans to directly market either of our products outside the United States. Given that we rely on Genentech to copromote Rituxan with us in the United States and rely exclusively on third parties to market Rituxan and Zevalin outside the United States, we cannot be certain that our products will be marketed and distributed in accordance with

our expectations or that our market research or sales forecasts will be accurate. We have no marketing support service experience and, therefore, we will be dependent on outside contractors to meet those needs. We rely upon a third-party logistics distributor to provide customer service, order entry, shipping and billing related to Zevalin. Customer reimbursement assistance related to Zevalin is provided by a separate outside contractor. We cannot assure you that the integration of these marketing support services can be successfully coordinated. Neither can we assure you that we will ever be able to develop our own marketing and sales capabilities to an extent that we would not need to rely on third-party efforts, or that we will be able to maintain satisfactory arrangements with the third parties on whom we rely.

Our Operating Results Are Subject to Significant Fluctuations.

Our quarterly revenues, expenses and operating results have fluctuated in the past and are likely to fluctuate significantly in the future. Fluctuation may result from a variety of factors, including:

• our achievement of product development objectives and milestones;

• demand and pricing for Rituxan and Zevalin;

• timing and nature of contract manufacturing and contract research and development payments and receipts;

• hospital and pharmacy buying decisions;

• clinical trial enrollment and expenses;

• research and development and manufacturing expenses;

• percentage of time that our manufacturing facilities are utilized for commercial versus clinical manufacturing;

• expenses related to protecting our intellectual property;

• physician acceptance of our products;

• government or private healthcare reimbursement policies;

• our manufacturing performance and capacity and that of our partners;

• amount and timing of sales orders for Rituxan by Genentech for customers in the United States, by Roche for customers outside the United States and by Zenyaku and Roche for customers in Japan;

• amount and timing of our sales orders for Zevalin for customers in the United States and, if approved in Europe, by Schering AG for customers outside the United States;

• rate and success of product approvals;

• timing of regulatory approval, if any, of competitive products and the rate of market penetration of competing products;

• collaboration obligations and copromotion payments we make or receive;

• interest rate fluctuations;

• foreign currency exchange rates; and

• overall economic conditions.

Our operating results during any one quarter do not necessarily suggest the anticipated results of future quarters.

We Are Subject to Uncertainties Regarding Healthcare Reimbursement and Reform.

Our ability to commercialize products successfully depends in part on the extent to which health care providers are reimbursed by governmental agencies, including the Center for Medicare and Medicaid Services, or CMS, private health insurers and other organizations, such as health maintenance organizations, for the cost of such products and related treatments. Our business could be harmed if health care payers or providers implement cost-containment measures, or if governmental agencies implement health care reform. For example, CMS has indicated it may issue a National Coverage Decision for the Zevalin therapeutic regimen which, if issued, might limit the patients and situations for which the Medicare program would provide reimbursement for Zevalin.

In addition, we cannot assure you that current or any future level of Medicare reimbursement for our products will be viewed favorably by health care providers and that they will prescribe our products as a result. For example, effective January 1, 2003, many anticancer drugs and biologics covered by the Medicare program, including Rituxan, were assigned new payment rates for use in the hospital outpatient setting. Although most patients do not receive Rituxan in the hospital outpatient setting and so the majority of patients will not be affected, this anomaly could cause some hospitals to decide not to provide Rituxan under certain circumstances. Also in January 2003,

CMS classified the Zevalin therapeutic regimen as a procedure under its Hospital Outpatient Prospective Payment System, or HOPPS, rather than a drug, causing the baseline reimbursement rate set by CMS for Zevalin to be subject to adjustment based on a geographic wage index. CMS applies this index to procedure payments under HOPPS to account for the regional variances in wages of hospital staff who perform health care services. As a result, in some lower-wage regions of the United States the level of reimbursement for Zevalin is less than the baseline rate and, consequently, less than the cost of acquiring the therapy. This anomaly could cause certain health care providers to decline to deliver the therapy in certain circumstances. On August 6, 2003, CMS released its draft rule for the 2004 HOPPS which includes proposed new payment rates for all outpatient services. Although under the draft rule payment for the Zevalin portion of the treatment will not be subject to the wage index, the proposed new payment rates will be less than current acquisition costs. We believe the proposed Zevalin payment rates for 2004 are in error and intend to work with CMS to rectify the error prior to implementation of the final rule. We cannot be certain that we will be successful in effecting a favorable change in the final rule. Further, when the Zevalin therapeutic regimen is administered in a private-practice setting, such as a free-standing imaging center, payment rates for the Zevalin imaging and therapy doses are set by the local Medicare carrier and so may differ from carrier to carrier. As a result, if a health care provider in this setting deems a reimbursement rate to be insufficient, it could influence his or her decision whether to use Zevalin versus an alternative anticancer drug.

We Face Uncertain Results of Clinical Trials for Our Potential Products.

Our future success depends in large part upon the results of clinical trials designed to assess the safety and efficacy of our potential products. The completion rate of clinical trials depends significantly upon the rate of patient enrollment. Our inability to enroll patients on a timely basis could result in increased expenses and product development delays, which could harm our business. We cannot assure you that patients enrolled in our clinical trials will respond to our product candidates, that any product candidate will be safe and effective or that data derived from the trials will be suitable for submission to the FDA or satisfactorily support a BLA, sBLA or NDA. Factors that affect patient enrollment include:

• size of patient population for the targeted disease;

• eligibility criteria;

• proximity of eligible patients to clinical sites;

• clinical trial protocols; and

• the existence of competing protocols, including competitive financial incentives for patients and clinicians, and existing approved drugs, including Rituxan.

Even if a trial is fully enrolled, significant uncertainties remain as to whether it will prove successful. For example, in September 2002 we announced that we will not pursue further development of IDEC-114 for patients with moderate-to-severe psoriasis. In addition, we announced during the second quarter of 2002 that all ongoing clinical trials for our anti-CD40L monoclonal antibody, IDEC-131, were put on hold. In May 2003, clinical hold on our Phase II clinical trial for IDEC-131 in immune thrombocytopenic purpura was removed. Our remaining clinical trials for IDEC-131 remain on hold. We cannot predict when, if ever, we will resume these clinical trials.

In addition, the length of time necessary to complete clinical trials and submit an application for marketing and manufacturing approvals varies significantly and may be difficult to predict. Failure to comply with extensive FDA regulations may result in delay, suspension or cancellation of a trial or the FDA’s refusal to accept test results. The FDA may also suspend our clinical trials at any time if it concludes that the participants are being exposed to unacceptable risks. Consequently, we cannot ensure that Phase I, Phase II, Phase III or Phase IV post-marketing testing will be completed timely or successfully, if at all, for any of our potential or existing products. Furthermore, success in preclinical and early clinical trials does not ensure that later-phase or large-scale trials will be successful.

Our Industry Is Intensely Competitive.

The biotechnology industry is intensely competitive and we may not be able to produce or acquire rights to new products with commercial potential. We compete with biotechnology and pharmaceutical companies that have been established longer than we have, have a greater number of products on the market, have greater financial and other resources and have other technological or competitive advantages. We also compete in the development of technologies and processes and in acquiring personnel and technology from academic institutions, government agencies, and other private and public research organizations. We cannot be certain that one or more of our competitors will not receive patent protection that dominates, blocks or adversely affects our product development or business; will benefit from significantly greater sales and marketing capabilities; or will not develop products that are accepted more widely than ours. For example, on June 30, 2003, one of our competitors, Corixa, along with its marketing partner Glaxo, received FDA approval for Bexxar, an investigational radioimmunotherapy for the treatment of low-grade or transformed low-grade NHL. If Corixa and/or Glaxo successfully markets Bexxar, our business could be harmed.

We are also aware of other potentially competitive biologic therapies for NHL in development.

We May Be Unable to Adequately Protect or Enforce Our Intellectual Property Rights or Secure Rights to Third-Party Patents and We Are Involved in Patent Litigation.

Our ability and the abilities of our partners to obtain and maintain patent and other protection for our products will affect our ability to compete. We are assigned, have rights to, or have exclusive licenses to a number of U.S. and foreign patents and patent applications. However, the pending patent applications may not issue as patents and, even if approved, our patent rights may not be upheld by a court or may be narrowed if challenged. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions. Our patent rights may not provide competitive advantages for our products and may be challenged, infringed upon or circumvented by our competitors.

In addition to patents, we rely on trade secrets and proprietary know-how that we seek to protect, in part, through confidentiality agreements with our partners, employees and consultants. These parties may breach our agreements and courts may not enforce the agreements, leaving us without adequate remedies. Further, our trade secrets may become known or be developed independently or patented by our competitors.

If it were ultimately determined that our claimed intellectual property rights are unenforceable, or that our use of our products infringes the rights of others, we may be required or may desire to obtain licenses to patents and other intellectual property held by third parties to develop, manufacture and market our products. We may not be able to obtain these licenses on commercially reasonable terms, if at all, and any licensed patents or intellectual property that we may obtain may not be valid or enforceable. In addition, the scope of intellectual property protection is subject to scrutiny and challenge by courts and other governmental bodies. Litigation and other proceedings concerning patents and proprietary technologies can be protracted, expensive and distracting to management and companies may sue competitors as a way of delaying the introduction of competitors’ products. Any litigation, including any interference proceedings to determine priority of inventions, oppositions to patents in foreign countries or litigation against our partners, may be costly and time-consuming and could harm our business.

Given the large number of patent filings in the biopharmaceutical field, our competitors may have filed applications or been issued patents and may obtain additional patents and proprietary rights relating to products or processes competitive with or similar to our products and processes. We cannot be certain that U.S. or foreign patents do not exist or will not issue that would harm our ability to commercialize our products and product candidates.

Patent Litigation Related to Rituxan

On May 28, 1999 and September 14, 2000, Glaxo filed two patent infringement lawsuits against Genentech. These suits assert that the manufacture, use, and sale of Rituxan infringes U.S. patents owned by Glaxo. In September 2002, Genentech and Glaxo agreed to a settlement of both of these lawsuits, under which Genentech and Glaxo dismissed with prejudice all claims made by each party in the lawsuits and dismissed with prejudice Glaxo’s appeal. The settlement resolves and ends all the patent infringement claims that Glaxo made against Genentech in these lawsuits.

Glaxo has also sued Roche in Germany asserting that MabThera (the European tradename for Rituxan) infringes three of Glaxo’s patents. On October 26, 2000, a German court handling the infringement suit issued a decision holding that the manufacture, use and sale of MabThera infringes patents held by Glaxo. Roche has appealed the decision and the appeal is pending. Independent of the infringement suit, Roche attacked the validity of Glaxo’s patents. As a result, all three patents have been revoked either before the corresponding German court or in opposition proceedings before the European Patent Office, or EPO. Glaxo has appealed these decisions. As a result, the German court handling the infringement issue has stalled the infringement lawsuit against Roche until the German Supreme Court and the Technical Board of Appeal of the EPO have finally decided on the validity of the patents in question. Roche does not expect this to occur before the end of 2004. Although we were not named in the suit, if Glaxo prevails in the infringement suit, our business could be harmed.

Patent Litigation Related to Zevalin

On September 10, 2001, we filed a lawsuit in the federal district court in the Southern District of California against Corixa and the University of Michigan seeking declaratory judgment that Zevalin and its use in the treatment of various B-cell NHLs does not infringe certain issued U.S. patents held by Corixa regarding products and processes relating to radioimmunotherapy, and a further declaration that the patents are invalid. On September 12, 2001, Corixa, Glaxo (Corixa’s marketing partner) and the University of Michigan filed a lawsuit in federal court in the District of Delaware against us for patent infringement. The lawsuit claims that we infringe the patents that are the subject of our declaratory judgment action against Corixa. The lawsuit against us seeks damages and to permanently enjoin us from selling Zevalin. This action has been transferred to the federal district court in the Southern District of California and has been consolidated with our lawsuit. We cannot predict or determine the outcome of this litigation. An unfavorable outcome in this matter could limit our ability to sell Zevalin, could require us to pay damages for past sales of Zevalin and could require that we obtain a license from third parties to sell Zevalin. Any such unfavorable outcome could harm our business and our results of operations.

On February 25, 2003, we filed an additional complaint against Corixa and Glaxo in the federal district court in the Southern District of California. The complaint alleges that Corixa’s and Glaxo’s conduct since ODAC’s recommendation for approval of Bexxar constitutes, or will constitute, infringement of a patent recently issued to us. The complaint seeks available remedies under patent laws, including monetary damages and permanent injunctive relief.

Proceedings Related to Anti-CD40L Antibodies

In September 1999, an interference to determine priority of inventorship was declared in the United States Patent and Trademark Office, or USPTO, between Dartmouth University’s patent application, which has been exclusively licensed to us, and Columbia University’s patent, which we believe has been exclusively licensed to Biogen, relating to anti-CD40L antibodies. In October 2001, the USPTO issued a decision concluding that there was no interference between the Dartmouth application and the Columbia patent. We appealed the decision to the Court of Appeals, Federal Circuit in December 2001. If the decision of the USPTO is upheld, the Columbia patent will remain in force and could be asserted against us.

We, along with other companies, have filed oppositions to a Japanese patent assigned to Immunex Corporation relating to anti-CD40L antibodies. We are also aware that oppositions have been filed in the EPO to granted European applications that have been licensed to us. Each of these applications contain claims relating to the use of anti-CD40L antibodies as a therapeutic agent. If the outcome of any of the oppositions is adverse, in whole or in part, it could result in the scope of some or all of the granted claims being limited, some or all of the granted claims being lost, the granted patent application not proceeding to a patent or our competitors having patent claims that may be asserted against us.

Potential Conflicts with Third-Party Patent Rights

We are aware of several third-party patents and patent applications, to the extent they issue as patents, that if successfully asserted against us may adversely affect our ability to make, use, offer to sell, sell and import our products. These third-party patents and patent applications may include a number of U.S. and foreign patents that relate to various aspects of our products and product candidates.

The owners or licensees of the owners of these patents, or any foreign patents, and patent applications, to the extent they issue as patents, may assert that one or more of our products infringe one or more claims of these patents. If legal action is commenced against us or our partners to enforce any of these patents and patent applications, to the extent they issue as patents, and the plaintiff in such action prevails, we could be prevented from practicing the subject matter claimed in such patents.

Failure to Obtain Product Approvals or Comply with Government Regulations Could Harm Our Business.

As pharmaceutical companies, we and our partners, contract manufacturers and suppliers are subject to rigorous and extensive regulation by governmental authorities in the United States and other countries. In the United States, our products cannot be marketed until they are approved by the FDA. Obtaining FDA approval involves the submission, among other information, of the results of preclinical and clinical studies on the product and requires

substantial time, effort and financial resources. The FDA will also conduct pre-licensing and regular post-licensing inspections of the facility or facilities at which the product is manufactured to determine compliance with cGMP. Rituxan and Zevalin are our only products that have received FDA approval, and we cannot assure you that our product candidates will be approved either in the United States or in other countries in a timely fashion, if at all. Failure to comply with FDA requirements, both before and after product approval, may subject us or our partners, contract manufacturers and suppliers to administrative or judicial sanctions, including FDA refusal to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, fines, injunctions and/or criminal prosecution.

We May Be Unable to Maintain Third-Party Research and Development Relationships.

Funding of our research and development efforts depends largely upon various arrangements with corporate partners and others who provide us with funding and who perform research and development with respect to our products. These corporate partners may generally terminate their arrangements with us at any time. These parties may develop products that compete with ours, and we cannot be certain that they will perform their contractual obligations or that any revenues will be derived from such arrangements. The failure of one or more of our corporate partners to achieve product development objectives could harm our ability to fund related programs and develop products.

Our Business Exposes Us to Product Liability Claims.

Our design, testing, development, manufacture and marketing of products involve an inherent risk of exposure to product liability claims and related adverse publicity. Insurance coverage is expensive and difficult to obtain and we may be unable to obtain coverage in the future on acceptable terms, if at all. Although we currently maintain product liability insurance for our products in amounts we believe to be commercially reasonable, we cannot be certain that the coverage limits of our insurance policies or those of our strategic partners will be adequate. If we are unable to obtain sufficient insurance at an acceptable cost or if a successful product liability claim is made against us, whether fully covered by insurance or not, our business could be harmed.

We May Not Be Able to Successfully Develop and Commence Operations at Our New Commercial and Clinical Manufacturing Facilities.

We own an 87-acre parcel of land and a building on adjacent property in Oceanside, California where we are developing commercial and clinical manufacturing facilities. We have limited experience in developing these types of facilities and may not be able to successfully develop or commence operations at these facilities. If we fail to successfully develop or commence operations at these new facilities, we may be unable to commercialize or meet demands for products we may develop in the future. We may encounter difficulties in designing, constructing and initiating these facilities, including:

• governmental regulation of our facilities, specifically FDA or comparable agency approvals required for the commercial manufacture of our products;

• public opinion regarding the impact of these facilities on nearby communities;

• construction delays, including obtaining necessary governmental approvals and permits;

• cost overruns;

• delays in design, shipment and installation of equipment for our facilities;

• natural disasters;

• other unforeseeable factors inherent in the construction process; and

• obtaining financing we may need to complete the facilities.

Even if we are able to successfully develop these facilities, we may not be able to do so in a cost-effective manner or in a time frame that is consistent with our expected future manufacturing needs or our future manufacturing needs may not be sufficient to allow the facility to be fully operational, which could harm our business.

Our Business Involves Environmental Risks.

Our business and the business of several of our strategic partners, including Genentech, involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Biologics manufacturing is extremely susceptible to product loss due to microbial or viral contamination, material equipment failure, or vendor or operator error. Although we believe that our safety procedures for handling and disposing of such materials complies with state and federal standards, there will always be the risk of accidental contamination or injury. In addition, microbial or viral contamination may cause the closure of a manufacturing facility for an extended period of time. By law, radioactive materials may only be disposed of at state-approved facilities. We currently store our radioactive materials on-site because the approval of a disposal site in California for all California-based companies has been delayed indefinitely. If and when a disposal site is approved, we may incur substantial costs related to the disposal of these materials. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business.

We Rely Upon Key Personnel.

Our success will depend, to a great extent, upon the experience, abilities and continued services of our executive officers and key scientific personnel. If we lose the services of any of these individuals, our business could be harmed. Our success also will depend upon our ability to attract and retain other highly qualified scientific, managerial, sales and manufacturing personnel and our ability to develop and maintain relationships with qualified clinical researchers. Competition for these personnel and relationships is intense and we compete with numerous pharmaceutical and biotechnology companies as well as with universities and non-profit research organizations. We may not be able to continue to attract and retain qualified personnel or develop and maintain relationships with clinical researchers.

Future Transactions May Harm Our Business or the Market Price of Our Securities.

We regularly review potential transactions related to technologies, products or product rights and businesses complementary to our business. These transactions could include:

• mergers;

• acquisitions;

• strategic alliances;

• licensing agreements; and

• copromotion agreements.

We may choose to enter into one or more of these transactions at any time, which may cause substantial fluctuations to the market price of securities that we have issued. Moreover, depending upon the nature of any transaction, we may experience a charge to earnings, which could also harm the market price of securities that we have issued.

Volatility of Our Stock Price.

The market prices for our common stock and for securities of other companies engaged primarily in biotechnology and pharmaceutical development, manufacture and distribution are highly volatile. For example, the market price of our common stock fluctuated between $27.80 per share and $42.15 per share during the six months ended June 30, 2003. The market price of our common stock likely will continue to fluctuate due to a variety of factors, including:

• material public announcements;

• the announcement and timing of new product introductions by us or others;

• technical innovations or product development by us or our competitors;

• regulatory approvals or regulatory issues;

• availability and level of third-party reimbursement;

• developments relating to patents, proprietary rights and orphan drug status;

• actual or potential clinical results with respect to our products under development or those of our competitors;

• political developments or proposed legislation in the pharmaceutical or healthcare industry;

• economic and other external factors, disaster or crisis;

• hedge and/or arbitrage activities by holders of our convertible promissory notes;

• period-to-period fluctuations in our financial results or results which do not meet or exceed analyst expectations; and

• market trends relating to or affecting stock prices throughout our industry, whether or not related to results or news regarding us or our competitors.

We May Be Unable to Raise Additional Capital.

We expend and will likely continue to expend substantial funds to complete the research, development, manufacturing and marketing of our potential future products. Consequently, we may seek to raise capital through collaborative arrangements, strategic alliances or equity and debt financings or from other sources. We may need to raise additional funds or borrow funds to complete the construction of our planned facilities. We may be unable to raise additional capital on commercially acceptable terms, if at all, and if we raise capital through equity financing, existing stockholders will have their ownership interests diluted. Our failure to generate adequate funds from operations or from additional sources to fund our business objectives would harm our business.

Our Outstanding LYONs Leverage Us Considerably.

As a result of issuing our LYONs due 2019 in February 1999 and issuing our LYONs due 2032 in April and May 2002, we incurred indebtedness of approximately $345.0 million at maturity in 2019 and approximately $1.2 billion at maturity in 2032. As a result of this indebtedness, our principal and interest obligations increased substantially. In addition, holders of our LYONs due 2032 may require us to purchase all or a portion of the LYONs on April 29, 2005, 2007, 2012 and 2017 at a price equal to the issue price plus the accrued original issue discount to the date of purchase, payable at our option in cash, our common stock or a combination thereof. The degree to which we are leveraged could harm our ability to obtain future financing and could make us more vulnerable to industry downturns and competitive pressures. Our ability to meet our debt obligations will be dependent upon our future performance, which will be subject to financial, business and other factors affecting our operations, many of which are beyond our control.

We Have Adopted Several Anti-takeover Measures.

A number of factors pertaining to our corporate governance discourage a takeover attempt that might be beneficial to stockholders who wish to receive a premium for their shares from a potential bidder. For example:

• we are subject to Section 203 of the Delaware General Corporation Law which provides that we may not enter into a business combination with an interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in the manner prescribed in the code section;

• our stockholder rights plan is designed to cause substantial dilution to a person who attempts to acquire us on terms not approved by our board of directors;

• our board of directors has the authority to issue, without vote or action of stockholders, up to 8,000,000 shares of preferred stock and to fix the price, rights, preferences and privileges of those shares. Any series of preferred stock could contain dividend rights, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences or other rights superior to the rights of holders of common stock. Although we had 36,214 shares of non-voting convertible preferred stock outstanding as of June 30, 2003, which were convertible into 2,172,840 shares of common stock, the board of directors has no present intention of issuing any additional shares of preferred stock. However, the board of directors may issue additional series of preferred stock in the future;

• our collaboration agreement with Genentech provides Genentech with the option to buy the rights to Rituxan and retain control of any additional anti-CD20 products developed under the collaboration in the event that we undergo a change of control, which may limit our attractiveness to potential acquirors;

• under the terms of the LYONs, any acquiror would be required to repurchase the LYONs for cash in connection with its acquisition of us before 2007; and

• our directors are elected to staggered terms which prevents the entire board from being replaced in any single year.

Our Proposed Merger With Biogen May Divert the Attention of Management.

Securing stockholder, regulatory and other required approvals of our proposed merger with Biogen will require the commitment of significant time from our senior officers. In addition, if the merger is approved and is completed, integrating the operations of the two companies will require significant attention by the management of both companies. To the extent that these responsibilities conflict with the other duties of these individuals, our business and prospects could be harmed.

Our Merger Agreement With Biogen Requires Payment of a Termination Fee of Up to $230 Million In Certain Instances, Which Could Deter a Third Party From Proposing an Alternative Transaction to the Merger.

Under the terms of our merger agreement with Biogen, we, Biogen or both of us may be required to pay to the other party a termination fee of up to $230 million if the merger agreement is terminated under certain circumstances. With some exceptions, these circumstances include, among others, (i) situations in which one party has terminated the merger agreement as a result of the withdrawal, modification or change in the recommendation of the other party’s board of directors with respect to the merger and (ii) certain other terminations if, prior to the termination, a third party announced an offer or indicated an interest in a transaction involving a party and/or, within 12 months of such termination, that party enters into a transaction involving the sale of that party, or the merger of that party, with another company. The effect of this termination fee may discourage competing bidders from presenting proposals to acquire or merge with us that, from a financial perspective, might be superior to the terms of the merger. Our financial position and results of operations would be adversely affected if we were required to pay the termination fee to Biogen.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to a variety of risks, including changes in interest rates affecting the return on our investments and the cost of our debt.

At June 30, 2003, we maintained a portion of our cash and cash equivalents in financial instruments with original maturities of three months or less. We also maintained an investment portfolio containing financial instruments in which the majority have original maturities of greater than three months but less than twenty-four months. These financial instruments, principally comprised of corporate obligations and U.S. government obligations, are subject to interest rate risk and will decline in value if interest rates increase. A hypothetical ten percent change in interest rates during the six months ended June 30, 2003, would have resulted in an approximately $0.8 million change in pretax income. We have not used derivative financial instruments in our investment portfolio.

Our long-term debt totaled $856.2 million at June 30, 2003 and was comprised solely of our subordinated notes which bear interest at 5.5% and our senior notes which bear interest at 1.75%. These long-term debt obligations bear interest at a weighted average interest rate of 2.4%. Due to the fixed rate nature of our convertible promissory notes, an immediate ten percent change in interest rates would not have a material effect on our financial condition or results of operations.

We are also exposed to market risk in that an increase in our stock price or an increase in interest rates may make conversion of our convertible promissory notes to common stock beneficial to the noteholders. Conversion of our convertible promissory notes would have a dilutive effect on our basic earnings per share and book value per common share.

Item 4. Controls and Procedures.

We performed an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based on that evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures are effective and provide for timely collection and evaluation of information that may need to be disclosed to investors.

There have been no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of our evaluation, nor were there any significant deficiencies or material weaknesses in our internal controls. Accordingly, no corrective actions with regard to significant deficiencies and material weaknesses were required or undertaken.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

On June 25, 2003, a suit was filed in the Superior Court of California, County of San Diego, on behalf of a purported class of Biogen stockholders against Biogen, us and certain members of Biogen’s board of directors alleging, among other things, that each of Biogen, us and the members of Biogen’s board of directors breached and/or aided in the breach of the other defendants’ breaches of their fiduciary duties of candor, loyalty, due care, independence, good faith and fair dealing by tailoring the structural terms of the merger to meet our specific needs rather than attempting to obtain the highest price reasonably available for Biogen. The complaint seeks, among other things, to enjoin or rescind the merger and to impose constructive trusts in favor of the plaintiff class. We and Biogen intend to defend this action vigorously.

Item 4. Submission of Matters to a Vote of Security Holders.

On May 19, 2003, we held our Annual Meeting of Stockholders at which the stockholders approved all of the proposals listed below:

(1) The election of Alan B. Glassberg, M.D., Robert W. Pangia, and William D. Young to the Board of Directors to serve for a three-year term ending in the year 2006, or until their successors shall have been duly elected or appointed or until their earlier death, resignation or removal.

(2) The amendment to our 1988 Stock Option Plan to increase the total number of shares of common stock authorized for issuance thereunder by an additional 5,700,00 shares from 58,580,000 shares to 64,280,000 shares.

(3) The amendment to the 1993 Non-Employee Directors Stock Option Plan to increase the annual non-statutory stock option grant to non-employee directors from 10,000 shares to 12,500 shares of common stock, effective with the January 2004 annual grant.

(4) The selection of KPMG LLP as our independent public accountants for the fiscal year ending December 31, 2003.

The following directors received the number of votes set opposite their respective names:

	For Election	Withheld
Alan B. Glassberg, M.D.	123,179,571	2,090,107
Robert W. Pangia	117,251,085	8,018,593
William D. Young	116,033,233	9,236,445

The proposal to amend the 1988 Stock Option Plan received 69,128,425 affirmative votes (for the amendment), 55,851,115 negative votes (against the amendment) and 290,136 votes abstained. The proposal did not receive any broker non-votes.

The proposal to amend the 1993 Non-Employee Directors Stock Option Plan received 112,951,293 affirmative votes (for the amendment), 12,060,185 negative votes (against the amendment) and 258,198 votes abstained. The proposal did not receive any broker non-votes.

The proposal to select KPMG LLP as our independent public accountants received 118,286,336 affirmative votes (for the selection), 6,814,768 negative votes (against the selection), and 168,574 votes abstained. This proposal did not receive any broker non-votes.

Item 6. Exhibits and Reports on Form 8-K.

(a) Exhibits referenced.

Exhibit Number		Description

2.1(1)		Agreement and Plan of Merger dated as of June 20, 2003.

3.1(2)		Form of the amendment to the Amended and Restated Certificate of Incorporation of the Registrant.

3.2(2)		Form of the amendment to the Bylaws of the Registrant.

4.2(1)		Amendment No. 1 to Amended and Restated Rights Agreement dated as of June 20, 2003.

10.1(3)		1988 Stock Option Plan (Amended and Restated through February 26, 2003).

10.14(4)		1993 Non-Employee Directors Stock Option Plan (Amended and Restated through February 26, 2003).

10.30(5)		Amended and Restated Collaboration Agreement dated as of June 19, 2003 between IDEC and Genentech, Inc.

10.71(2)		Employment Agreement dated as of June 20, 2003 between IDEC and William H. Rastetter, Ph.D.

10.72(2)		Employment Agreement dated as of June 20, 2003 between IDEC and James C. Mullen.

31.1		Certifications of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, filed as an exhibit hereto.

32.1		Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, furnished as an exhibit hereto.

(1) Incorporated by reference to exhibit filed with our Current Report on Form 8-K, dated June 23, 2003.

(2) Incorporated by reference to exhibit filed with our Registration Statement on Form S-4, File No.333-107098.

(3) Incorporated by reference to exhibit filed with our Registration Statement on Form S-8, File No. 333-106794.

(4) Incorporated by reference to our Definitive Proxy Statement dated April 14, 2003.

(5) Incorporated by reference to exhibit filed with our Current Report on Form 8-K, dated July 31, 2003.

(b) Reports on Form 8-K.

On June 23, 2003, we filed a current report on Form 8-K reporting that we had entered into a merger agreement with Biogen, Inc.

On July 17, 2003, we filed a current report on Form 8-K reporting that we issued a press release regarding our financial results for the three months ended June 30, 2003 on July 17, 2003.

On July 31, 2003, we filed a current report on Form 8-K reporting that we had entered into an amended and restated collaboration agreement with Genentech, Inc.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		IDEC PHARMACEUTICALS CORPORATION


Date:	August 14, 2003	By:	/s/ William H. Rastetter, Ph.D.
			William H. Rastetter, Ph.D.
			Chairman of the Board and Chief Executive Officer (Principal Executive Officer)

Date:	August 14, 2003	By:	/s/ Edward M. Rodriguez
			Edward M. Rodriguez
			Vice President, Finance and Controller (Principal Financial and Accounting Officer)